Indications
Rasagiline ratiopharm is indicated for the treatment of idiopathic Parkinson’s disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.
Composition
- Active substance
- rasagiline
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Rasagiline ratiopharm
- Active substance
- rasagiline
- ATC code
- N04BD02
- Group
- Nervous system
- Therapeutic area
- Parkinson Disease
- Marketing authorisation holder
- Teva B.V.
- Status
- Authorised
- EU authorisation